# NAC Respiratory Infection Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/nac-respiratory-infection-meta-analysis-evidence-review
Category: evidence-review
Summary: NAC Respiratory Infection Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are
Last reviewed: 2026-06-25
Reviewed by: Migaku Evidence Review
# NAC Respiratory Infection Meta-analysis: What the Evidence Says

## Quick Answer

NAC Respiratory Infection Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are guideline, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 guideline, 1 research article.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| N-acetylcysteine: evidence based consensus document on the therapeutic advantages in respiratory diseases (NECTAR). | guideline | 2 | 2026-05-04 | 10.3389/fmed.2026.1810363 |
| Mucoactive Agents in Muco-Obstructive Lung Diseases: A Critical Reappraisal of Pharmacological Effects and Clinical Outcomes. | research article | 4 | 2026-04-27 | 10.3390/ph19050681 |

## What The Sources Report

- This document consolidates existing evidence to this effect, and adds insights from practicing clinicians to guide about use of NAC in clinical practice. [Barne M (2026); evidence level 2]
- Conclusion This consensus underscores the role of NAC in chronic respiratory diseases beyond its mucolytic properties and reiterates that NAC's antioxidant, anti-inflammatory, immunomodulatory and anti-biofilm properties provide significant clinical utility. [Barne M (2026); evidence level 2]
- Clinical evidence indicates that NAC and erdosteine can reduce exacerbation rates in COPD, carbocisteine shows benefit with prolonged administration, and dornase alfa remains a cornerstone in CF management. [Larobina D (2026); evidence level 4]
- Emerging strategies, such as agents targeting mucin-DNA interactions and advanced inhalation delivery systems, promise improved specificity and durability. [Larobina D (2026); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

For NAC respiratory infection meta-analysis, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Barne M (2026). N-acetylcysteine: evidence based consensus document on the therapeutic advantages in respiratory diseases (NECTAR).. DOI: 10.3389/fmed.2026.1810363. PMCID: PMC13180745. PMID: 42158130. https://pmc.ncbi.nlm.nih.gov/articles/PMC13180745/
- Larobina D (2026). Mucoactive Agents in Muco-Obstructive Lung Diseases: A Critical Reappraisal of Pharmacological Effects and Clinical Outcomes.. DOI: 10.3390/ph19050681. PMCID: PMC13209488. PMID: 42198355. https://pmc.ncbi.nlm.nih.gov/articles/PMC13209488/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.